化疗引起的急性髓系白血病骨髓抑制的防治进展

Progress in the Management of Chemotherapy-Induced Myelosuppression in AML

急性髓系白血病(Acute Myeloid Leukemia, AML)是常见的血液恶性肿瘤,其发病率逐年提高,目前采用的主要治疗方式是联合序贯化疗,由于其化疗强度大,骨髓抑制深,因此为提高患者缓解率,需加强对骨髓抑制期的重视,以减轻患者的心理及经济压力。

Acute myeloid leukemia (AML) is a common haematological malignancy, and its incidence is increasing year by year. The main treatment modality currently used is combined sequential chemotherapy, due to the high intensity of chemotherapy and deep myelosuppression, therefore, in order to improve the remission rate of the patients, it is necessary to strengthen the attention to the myelosuppression period, in order to alleviate the psychological and economic pressure on the patients.